Aura Biosciences, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2025 Annual Meeting of Stockholders held by Aura Biosciences, Inc. on June 17, 2025. The filing details the voting results for director elections and the ratification of the independent registered accounting firm.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
At the Annual Meeting, 38,863,371 shares were present or represented by proxy out of 50,268,758 shares entitled to vote. The following proposals were approved:
- Proposal 1 - Election of Directors: Stockholders elected Elisabet de los Pinos, Ph.D., and Giovanni Mariggi, Ph.D., as Class I directors to serve until the 2028 Annual Meeting.
- Elisabet de los Pinos: 28,961,014 votes for; 985,262 votes withheld; 8,917,095 broker non-votes.
- Giovanni Mariggi: 29,179,073 votes for; 767,203 votes withheld; 8,917,095 broker non-votes.
- Proposal 2 - Ratification of Accounting Firm: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Votes For: 38,623,566
- Votes Against: 232,989
- Abstentions: 6,816
- Broker Non-Votes: 0
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation of the new director term ending at the 2028 Annual Meeting.
- Verification of the high volume of broker non-votes (8,917,095) on the director election proposal.
- Confirmation that Ernst & Young LLP will serve as the auditor for the fiscal year ending December 31, 2025.
- Review of the definitive proxy statement filed on April 24, 2025, for detailed background on the nominees and proposals.